ITOS
iTeos Therapeutics, Inc.
- Latest sale
- $1M
- Jun 10 · Routine
- Form 4 sales
- 95
- On record
- Form 144 notices
- 1
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 144 noticeNoticeAug 23 2023
Filed to sell 350,000 shares ($4.1M)
Boxer Capital, LLC, Seller's CEO is Director of Issuer
No 10b5-1 planFiling
- 2 Form 4 saleNo planAug 23 same day
Sold 350,000 shares at $16.26 ($5.7M)
Davis Aaron I., Other
No 10b5-1 planSold 16.2% of holdings ($35M position)1.8M shares leftFiling
- 3 Form 4 saleNo planMay 13 +629 days
Sold 630,191 shares at $8.06 ($5.1M)
Mpm Bioventures 2018 (b), L.P., Other
No 10b5-1 planSold 23% of holdings ($22.1M position)2.1M shares leftFirst sale on recordFiling
- 4 Form 4 saleNo planMay 13 same day
Sold 630,191 shares at $8.06 ($5.1M)
MPM BioVentures 2018 GP LLC, Other
No 10b5-1 planSold 23% of holdings ($22.1M position)2.1M shares leftFirst sale on recordFiling
- 5 Form 4 saleNo planMay 13 same day
Sold 1M shares at $8.06 ($8.3M)
MPM BioImpact LLC, Other
No 10b5-1 planSold 23% of holdings ($36.1M position)3.5M shares leftFirst sale on recordFiling
- 6 Form 4 saleRoutineJun 6 +24 days
Sold 114,682 shares at $10.15 ($1.2M)
Hallal David, Director
10b5-1 planSold 100% of holdings ($1.2M position)0 shares leftFirst sale on recordFiling
- 7 Form 4 saleRoutineJun 6 same day
Sold 156,847 shares at $10.15 ($1.6M)
Detheux Michel, Chief Executive Officer
10b5-1 planSold 53.6% of holdings ($3M position)135,903 shares leftFirst sale on recordFiling
- 8 Form 4 saleRoutineJun 10 +4 days
Sold 104,565 shares at $10.02 ($1M)
Detheux Michel, Chief Executive Officer
10b5-1 planSold 43.5% of holdings ($2.4M position)135,903 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (96)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Detheux Michel | Chief Executive Officer | Form 4 sale | 104,565 | $1M | 43.5% | Routine | SEC |
| Jun 6, 2025 | Detheux Michel | Chief Executive Officer | Form 4 sale | 156,847 | $1.6M | 53.6% | Routine | SEC |
| Jun 6, 2025 | Hallal David | Director | Form 4 sale | 114,682 | $1.2M | 100.0% | Routine | SEC |
| May 13, 2025 | MPM BioImpact LLC | Other | Form 4 sale | 1M | $8.3M | 23.0% | No plan | SEC |
| May 13, 2025 | MPM BioVentures 2018 GP LLC | Other | Form 4 sale | 630,191 | $5.1M | 23.0% | No plan | SEC |
| May 13, 2025 | Mpm Bioventures 2018 (b), L.P. | Other | Form 4 sale | 630,191 | $5.1M | 23.0% | No plan | SEC |
| Aug 23, 2023 | Davis Aaron I. | Other | Form 4 sale | 350,000 | $5.7M | 16.2% | No plan | SEC |
| Aug 23, 2023 | Boxer Capital, LLC | Seller's CEO is Director of Issuer | Form 144 notice | 350,000 | $4.1M | Notice | SEC | |
| Jun 9, 2022 | Hallal David | Director | Form 4 sale | 29,615 | $597k | 100.0% | Unusual | SEC |
| May 11, 2022 | Davis Aaron I. | Director | Form 4 sale | 663,000 | $14M | 23.5% | Plan not stated | SEC |
| May 2, 2022 | Davis Aaron I. | Director | Form 4 sale | 375,000 | $10.2M | 11.7% | Plan not stated | SEC |
| Apr 18, 2022 | Detheux Michel | Chief Executive Officer | Form 4 sale | 11,500 | $367k | 30.5% | Unusual | SEC |
| Mar 22, 2022 | Detheux Michel | Chief Executive Officer | Form 4 sale | 18,437 | $630k | 41.2% | Unusual | SEC |
| Mar 17, 2022 | Boxer Capital, LLC | 10% owner | Form 4 sale | 575,201 | $20.3M | 15.5% | Plan not stated | SEC |
| Mar 11, 2022 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 3,500 | $126k | 100.0% | Unusual | SEC |
| Mar 1, 2022 | McGrath Yvonne | Chief Scientific Officer | Form 4 sale | 10,000 | $368k | 100.0% | Unusual | SEC |
| Feb 23, 2022 | Detheux Michel | Chief Executive Officer | Form 4 sale | 14,500 | $498k | 29.5% | Unusual | SEC |
| Feb 11, 2022 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 3,500 | $125k | 100.0% | Unusual | SEC |
| Jan 25, 2022 | Detheux Michel | Chief Executive Officer | Form 4 sale | 14,500 | $517k | 22.8% | Plan not stated | SEC |
| Jan 14, 2022 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 3,500 | $138k | 100.0% | Unusual | SEC |
| Jan 5, 2022 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 146,685 | $6.2M | 5.1% | Unusual | SEC |
| Jan 5, 2022 | Mpm Asset Management Investors Bv2018 LLC | 10% owner | Form 4 sale | 146,685 | $6.2M | 5.1% | Plan not stated | SEC |
| Jan 5, 2022 | Gadicke Ansbert | 10% owner | Form 4 sale | 245,469 | $10.5M | 5.2% | Unusual | SEC |
| Jan 4, 2022 | MVA Investors, LLC | 10% owner | Form 4 sale | 700,000 | $32.6M | 100.0% | Unusual | SEC |
| Jan 3, 2022 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 7,000 | $363k | 100.0% | Unusual | SEC |
| Jan 3, 2022 | Biniszkiewicz Detlev | Director | Form 4 sale | 3,500 | $182k | 100.0% | Unusual | SEC |
| Dec 27, 2021 | Gall Matthew | Chief Financial Officer | Form 4 sale | 5,000 | $232k | 25.7% | Unusual | SEC |
| Dec 22, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 44,500 | $2M | 41.1% | Unusual | SEC |
| Dec 20, 2021 | Hallal David | Director | Form 4 sale | 50,000 | $2.2M | 100.0% | Unusual | SEC |
| Dec 17, 2021 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 7,000 | $287k | 100.0% | Unusual | SEC |
| Dec 10, 2021 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 3,500 | $121k | 100.0% | Unusual | SEC |
| Dec 7, 2021 | Mpm Bioventures 2018, L.P. | 10% owner | Form 4 sale | 49,831 | $1.7M | 1.7% | Plan not stated | SEC |
| Dec 7, 2021 | Mpm Bioventures 2018 (b), L.P. | 10% owner | Form 4 sale | 49,831 | $1.7M | 1.7% | Plan not stated | SEC |
| Dec 7, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 83,390 | $2.8M | 1.7% | Plan not stated | SEC |
| Dec 2, 2021 | MPM BioVentures 2018 LLC | 10% owner | Form 4 sale | 83,519 | $2.9M | 2.8% | Plan not stated | SEC |
| Dec 2, 2021 | Evnin Luke | 10% owner | Form 4 sale | 83,519 | $2.9M | 2.8% | Plan not stated | SEC |
| Dec 2, 2021 | BioImpact Capital LLC | 10% owner | Form 4 sale | 139,773 | $4.8M | 2.8% | Unusual | SEC |
| Nov 29, 2021 | MPM BioVentures 2018 LLC | 10% owner | Form 4 sale | 23,045 | $811k | 0.8% | Plan not stated | SEC |
| Nov 29, 2021 | Mpm Bioventures 2018 (b), L.P. | 10% owner | Form 4 sale | 23,045 | $811k | 0.8% | Plan not stated | SEC |
| Nov 29, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 38,566 | $1.4M | 0.8% | Plan not stated | SEC |
| Nov 24, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 129,617 | $4.7M | 2.5% | Plan not stated | SEC |
| Nov 24, 2021 | MPM BioVentures 2018 LLC | 10% owner | Form 4 sale | 77,455 | $2.8M | 2.5% | Plan not stated | SEC |
| Nov 24, 2021 | Evnin Luke | 10% owner | Form 4 sale | 77,455 | $2.8M | 2.5% | Plan not stated | SEC |
| Nov 23, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 14,500 | $523k | 15.6% | Plan not stated | SEC |
| Nov 18, 2021 | Lager Joanne Jenkins | Chief Medical Officer | Form 4 sale | 28,000 | $966k | 100.0% | Unusual | SEC |
| Nov 3, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 20,557 | $587k | 21.2% | Plan not stated | SEC |
| Oct 21, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 196 | $5k | 0.2% | Plan not stated | SEC |
| Oct 19, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 1,836 | $51k | 1.9% | Plan not stated | SEC |
| Oct 18, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 17,099 | $469k | 0.5% | Plan not stated | SEC |
| Oct 18, 2021 | MPM BioVentures 2014, L.P. | 10% owner | Form 4 sale | 17,099 | $469k | 0.5% | Plan not stated | SEC |
| Oct 18, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 28,615 | $785k | 0.6% | Plan not stated | SEC |
| Oct 14, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 56,770 | $1.5M | 1.8% | Plan not stated | SEC |
| Oct 14, 2021 | MPM BioVentures 2014, L.P. | 10% owner | Form 4 sale | 56,770 | $1.5M | 1.8% | Plan not stated | SEC |
| Oct 14, 2021 | Gadicke Ansbert | 10% owner | Form 4 sale | 95,002 | $2.6M | 1.8% | Plan not stated | SEC |
| Oct 11, 2021 | Mpm Bioventures 2018, L.P. | 10% owner | Form 4 sale | 51,993 | $1.4M | 1.6% | Plan not stated | SEC |
| Oct 11, 2021 | Foley Todd | 10% owner | Form 4 sale | 51,993 | $1.4M | 1.6% | Plan not stated | SEC |
| Oct 11, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 87,006 | $2.4M | 1.6% | Plan not stated | SEC |
| Oct 4, 2021 | Mpm Bioventures 2018, L.P. | 10% owner | Form 4 sale | 27,566 | $746k | 0.8% | Plan not stated | SEC |
| Oct 4, 2021 | Evnin Luke | 10% owner | Form 4 sale | 27,566 | $746k | 0.8% | Plan not stated | SEC |
| Oct 4, 2021 | Gadicke Ansbert | 10% owner | Form 4 sale | 46,130 | $1.2M | 0.9% | Plan not stated | SEC |
| Sep 30, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 21,506 | $581k | 0.6% | Plan not stated | SEC |
| Sep 30, 2021 | MPM BioVentures 2014 LLC | 10% owner | Form 4 sale | 21,506 | $581k | 0.6% | Plan not stated | SEC |
| Sep 30, 2021 | BioImpact Capital LLC | 10% owner | Form 4 sale | 35,990 | $972k | 0.7% | Plan not stated | SEC |
| Sep 27, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 53,468 | $1.5M | 1.6% | Plan not stated | SEC |
| Sep 27, 2021 | Evnin Luke | 10% owner | Form 4 sale | 53,468 | $1.5M | 1.6% | Plan not stated | SEC |
| Sep 27, 2021 | UBS Oncology Impact Fund L.P. | 10% owner | Form 4 sale | 89,476 | $2.5M | 1.6% | Plan not stated | SEC |
| Sep 24, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 6,411 | $180k | 6.1% | Plan not stated | SEC |
| Sep 22, 2021 | Mpm Bioventures 2018, L.P. | 10% owner | Form 4 sale | 33,929 | $933k | 1.0% | Plan not stated | SEC |
| Sep 22, 2021 | MPM Asset Management Investors BV2014 LLC | 10% owner | Form 4 sale | 33,929 | $933k | 1.0% | Plan not stated | SEC |
| Sep 22, 2021 | Gadicke Ansbert | 10% owner | Form 4 sale | 56,779 | $1.6M | 1.0% | Plan not stated | SEC |
| Sep 20, 2021 | Foley Todd | 10% owner | Form 4 sale | 91,254 | $2.6M | 2.6% | Plan not stated | SEC |
| Sep 20, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 91,254 | $2.6M | 2.6% | Plan not stated | SEC |
| Sep 20, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 152,711 | $4.3M | 2.7% | Plan not stated | SEC |
| Sep 15, 2021 | MPM BioVentures 2014, L.P. | 10% owner | Form 4 sale | 45,665 | $1.3M | 1.3% | Plan not stated | SEC |
| Sep 15, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 45,665 | $1.3M | 1.3% | Plan not stated | SEC |
| Sep 15, 2021 | Gadicke Ansbert | 10% owner | Form 4 sale | 76,417 | $2.1M | 1.3% | Plan not stated | SEC |
| Sep 13, 2021 | BioImpact Capital LLC | 10% owner | Form 4 sale | 96,456 | $2.7M | 1.6% | Plan not stated | SEC |
| Sep 13, 2021 | Evnin Luke | 10% owner | Form 4 sale | 57,640 | $1.6M | 1.6% | Plan not stated | SEC |
| Sep 13, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 57,640 | $1.6M | 1.6% | Plan not stated | SEC |
| Sep 8, 2021 | Oncology Impact Fund (Cayman) Management L.P. | 10% owner | Form 4 sale | 71,232 | $2.1M | 1.2% | Plan not stated | SEC |
| Sep 8, 2021 | Mpm Bioventures 2018 (b), L.P. | 10% owner | Form 4 sale | 42,566 | $1.2M | 1.2% | Plan not stated | SEC |
| Sep 8, 2021 | Mpm Bioventures 2018, L.P. | 10% owner | Form 4 sale | 42,566 | $1.2M | 1.2% | Plan not stated | SEC |
| Sep 2, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 20,252 | $581k | 16.1% | Plan not stated | SEC |
| Aug 31, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 14,663 | $412k | 10.4% | Plan not stated | SEC |
| Aug 25, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 8,585 | $241k | 5.8% | Plan not stated | SEC |
| Jun 14, 2021 | Detheux Michel | Chief Executive Officer | Form 4 sale | 29,000 | $826k | 16.3% | Plan not stated | SEC |
| Jun 8, 2021 | McGrath Yvonne | VP, Research and Development | Form 4 sale | 7,927 | $159k | 100.0% | Unusual | SEC |
| Jun 2, 2021 | McGrath Yvonne | VP, Research and Development | Form 4 sale | 7,927 | $160k | 100.0% | Unusual | SEC |
| May 24, 2021 | McGrath Yvonne | VP, Research and Development | Form 4 sale | 7,927 | $174k | 100.0% | Unusual | SEC |
| May 17, 2021 | McGrath Yvonne | VP, Research and Development | Form 4 sale | 7,926 | $196k | 100.0% | Unusual | SEC |
| Apr 9, 2021 | MPM BioVentures 2014, L.P. | 10% owner | Form 4 sale | 119 | $4k | 0.0% | Plan not stated | SEC |
| Apr 9, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 119 | $4k | 0.0% | Plan not stated | SEC |
| Apr 9, 2021 | MPM Oncology Impact Management LP | 10% owner | Form 4 sale | 200 | $6k | 0.0% | Plan not stated | SEC |
| Apr 8, 2021 | MPM Oncology Impact Management LP | 10% owner | Form 4 sale | 41,982 | $1.3M | 0.7% | Plan not stated | SEC |
| Apr 8, 2021 | Mpm Asset Management Investors Bv2018 LLC | 10% owner | Form 4 sale | 25,087 | $777k | 0.7% | Plan not stated | SEC |
| Apr 8, 2021 | MPM BioVentures 2018 GP LLC | 10% owner | Form 4 sale | 25,087 | $777k | 0.7% | Plan not stated | SEC |